Abstract

Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4% of patients present with a solitary pulmonary nodule. Surgical resection can be an option for these patients and is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines. There are no prospective randomized clinical trials evaluating the role of adjuvant systemic therapy in these resected SCLC patients. A recent National Cancer Database analysis found that the receipt of adjuvant chemotherapy alone [hazard ratio (HR), 0.78; 95% CI, 0.63-0.95] or with brain radiation (HR, 0.52; 95% CI, 0.36-0.75) was associated with significantly improved survival as compared to surgery alone. As it is unlikely that a randomized prospective clinical trial addressing this question will be completed, these data should assist with decision making in these patients.

Original languageEnglish (US)
Pages (from-to)E755-E757
JournalJournal of Thoracic Disease
Volume8
Issue number8
DOIs
StatePublished - 2016

Fingerprint

Small Cell Lung Carcinoma
Randomized Controlled Trials
Solitary Pulmonary Nodule
Adjuvant Chemotherapy
Neoplasms
Decision Making
Databases
Guidelines
Radiation
Neoplasm Metastasis
Survival
Brain
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Small cell lung cancer (SCLC)
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Resected small cell lung cancer-time for more? / Marr, Alissa S; Zhang, Chi; Ganti, Apar Kishor P.

In: Journal of Thoracic Disease, Vol. 8, No. 8, 2016, p. E755-E757.

Research output: Contribution to journalArticle

@article{c84c0d091763454384600c32dea83eaa,
title = "Resected small cell lung cancer-time for more?",
abstract = "Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4{\%} of patients present with a solitary pulmonary nodule. Surgical resection can be an option for these patients and is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines. There are no prospective randomized clinical trials evaluating the role of adjuvant systemic therapy in these resected SCLC patients. A recent National Cancer Database analysis found that the receipt of adjuvant chemotherapy alone [hazard ratio (HR), 0.78; 95{\%} CI, 0.63-0.95] or with brain radiation (HR, 0.52; 95{\%} CI, 0.36-0.75) was associated with significantly improved survival as compared to surgery alone. As it is unlikely that a randomized prospective clinical trial addressing this question will be completed, these data should assist with decision making in these patients.",
keywords = "Adjuvant chemotherapy, Small cell lung cancer (SCLC), Surgery, Survival",
author = "Marr, {Alissa S} and Chi Zhang and Ganti, {Apar Kishor P}",
year = "2016",
doi = "10.21037/jtd.2016.07.17",
language = "English (US)",
volume = "8",
pages = "E755--E757",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "8",

}

TY - JOUR

T1 - Resected small cell lung cancer-time for more?

AU - Marr, Alissa S

AU - Zhang, Chi

AU - Ganti, Apar Kishor P

PY - 2016

Y1 - 2016

N2 - Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4% of patients present with a solitary pulmonary nodule. Surgical resection can be an option for these patients and is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines. There are no prospective randomized clinical trials evaluating the role of adjuvant systemic therapy in these resected SCLC patients. A recent National Cancer Database analysis found that the receipt of adjuvant chemotherapy alone [hazard ratio (HR), 0.78; 95% CI, 0.63-0.95] or with brain radiation (HR, 0.52; 95% CI, 0.36-0.75) was associated with significantly improved survival as compared to surgery alone. As it is unlikely that a randomized prospective clinical trial addressing this question will be completed, these data should assist with decision making in these patients.

AB - Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4% of patients present with a solitary pulmonary nodule. Surgical resection can be an option for these patients and is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines. There are no prospective randomized clinical trials evaluating the role of adjuvant systemic therapy in these resected SCLC patients. A recent National Cancer Database analysis found that the receipt of adjuvant chemotherapy alone [hazard ratio (HR), 0.78; 95% CI, 0.63-0.95] or with brain radiation (HR, 0.52; 95% CI, 0.36-0.75) was associated with significantly improved survival as compared to surgery alone. As it is unlikely that a randomized prospective clinical trial addressing this question will be completed, these data should assist with decision making in these patients.

KW - Adjuvant chemotherapy

KW - Small cell lung cancer (SCLC)

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84990233847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990233847&partnerID=8YFLogxK

U2 - 10.21037/jtd.2016.07.17

DO - 10.21037/jtd.2016.07.17

M3 - Article

VL - 8

SP - E755-E757

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 8

ER -